NeoFuse

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Degenerative Disc Disease

Conditions

Degenerative Disc Disease, Spondylolisthesis, Spinal Stenosis

Trial Timeline

Oct 1, 2007 → Sep 1, 2013

NCT ID

NCT00549913

About NeoFuse

NeoFuse is a phase 1/2 stage product being developed by Mesoblast for Degenerative Disc Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00549913. Target conditions include Degenerative Disc Disease, Spondylolisthesis, Spinal Stenosis.

What happened to similar drugs?

1 of 6 similar drugs in Degenerative Disc Disease were approved

Approved (1) Terminated (1) Active (4)

✅PimavanserinAcadia PharmaceuticalsApproved

❌LatozinemabAlectorPhase 3

🔄Pimavanserin + PlaceboAcadia PharmaceuticalsPhase 3

🔄PimavanserinAcadia PharmaceuticalsPhase 3

🔄Rexlemestrocel-L + HA mixture + SalineMesoblastPhase 3

🔄Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + PlaceboMesoblastPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01097486	Phase 2	Completed	Jun 1, 2010	Jul 1, 2014	Cervical Degenerative Disc Disease
NCT01106417	Phase 1/2	Completed	Jun 1, 2010	Mar 1, 2013	Cervical Degenerative Disc Disease
NCT00549913	Phase 1/2	Completed	Oct 1, 2007	Sep 1, 2013	Degenerative Disc Disease

Competing Products

17 competing products in Degenerative Disc Disease

See all competitors

Product	Company	Stage	Hype Score
Latozinemab	Alector	Phase 3	22
YH14618 + YH14618 + YH14618 + Placebo	Yuhan	Phase 1/2	32
Placebo + YH14618	Yuhan	Phase 2	35
Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells	Astellas Pharma	Phase 1/2	39
ONO-2808 + Placebo	Ono Pharmaceutical	Phase 1	29
Pimavanserin + Placebo	Acadia Pharmaceuticals	Phase 3	37
Pimavanserin	Acadia Pharmaceuticals	Approved	47
Pimavanserin	Acadia Pharmaceuticals	Phase 3	37
Lumbar Interbody Fusion with Autograft + Lumbar Interbody Fusion with NeoFuse + Lumbar Interbody Fusion with NeoFuse	Mesoblast	Phase 2	29
NeoFuse	Mesoblast	Phase 2	29
Rexlemestrocel-L + HA mixture + Saline	Mesoblast	Phase 3	41
Single Dose MPCs Injection + Single Dose MPCs Injection	Mesoblast	Phase 2	29
Rexlemestrocel-L + Rexlemestrocel-L + HA Mixture + Placebo	Mesoblast	Phase 3	34
NeoFuse	Mesoblast	Phase 1/2	26
PLF with NeoFuse + PLF with NeoFuse + PLF with NeoFuse	Mesoblast	Phase 1/2	18
Use iliac bone graft + use bone morphogenetic protein + use bone derived allograft MSCs + Use adipose tissue derived MSCs + Use amnion/placental derived MSCs	Brain Biotech	Phase 2/3	28
Blood sampling, skin biopsy, excreta sampling, lumbar puncture	Brain Biotech	Pre-clinical	23